---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-24-000009"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:52:56.102302+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Q4 rev ~$6.2-6.4M (+45%); FY rev ~$22.4-22.6M (+30%); cash $95M runway into H2 2026

## Summary
- Q4 revenue expected $6.2-6.4M (+45% YoY); FY23 revenue $22.4-22.6M (+30% YoY).
- Placed 16 Growth Direct systems in FY23, 6 in Q4; 18 validations completed in FY23.
- Cash and investments ~$95M as of Dec 31, 2023; cash runway at least into H2 2026.
- Growth Direct selected by Samsung Biologics; systems now placed with 100% of commercial CAR-T manufacturers.
- Commercial launch of Growth Direct Rapid Sterility app expected by mid-2024.

## SEC filing metadata
- accession: 0001380106-24-000009
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000009/0001380106-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000009/rpid-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-24-000009
- JSON: https://secwatch.observer/filing/0001380106-24-000009.json
- Plain text: https://secwatch.observer/filing/0001380106-24-000009.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: preliminary results
  source text: On January 10, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000009/0001380106-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.